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Letters to the EditorAcoustic radiation force-based shear stiffness
and non-invasive panels of tests in Japanese patients
with nonalcoholic fatty liver diseaseTo the Editor:
We read the article by Palmeri et al. [1] with great interest. The
authors concluded that Acoustic Radiation Force Impulse (ARFI)
shear stiffness, in which shear wave speed is converted using
the formula: shear stiffness (kPa) = (shear wave speed)2  den-
sity (1.0 g/cm2) [2], is clinically useful for assessing advanced
ﬁbrosis (stage 3–4) in patients with nonalcoholic fatty liver dis-
ease (NAFLD). We also previously reported that ARFI shear wave
speed can be used to measure advanced ﬁbrosis in patients with
NAFLD [3]. By using the cutoff of P4.24 kPa for detecting
advanced ﬁbrosis as proposed by Palmeri et al. in their paper,
we obtained a sensitivity of 80.0% and a speciﬁcity of 97.7% even
in our population (n = 54). Their study is clinically useful and
valuable, because the degree of liver ﬁbrosis must be estimated
for detecting the prognosis, conducting close surveillance, and
providing optimal treatment of patients with NAFLD. Because
liver biopsy is invasive and is associated with a relatively high
risk of complications [4], a rapid and non-invasive method of
detecting ﬁbrosis in patients with NAFLD is of major clinical
interest.
In their report, Palmeri et al. compared the liver stiffness
measures with the AST-to-platelet ratio index (APRI). Numerous
non-invasive panels of tests have been developed to stage liver
diseases, including a combination of clinical and routine labora-
tory parameters. Of these, the FIB4 score [5] and NAFLD ﬁbrosis
score [6] have been reported to be superior to APRI for detecting
advanced ﬁbrosis in NAFLD patients [7]. Therefore, we studied
the reliability of the shear stiffness in comparison with that of
the FIB4 score, and NAFLD ﬁbrosis score in Japanese patients with
NAFLD.FI
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Fig. 1. Correlation between shear stiffness and (A) the FIB4 score (r = 0.365,
p = 0.0063), (B) NAFLD ﬁbrosis score (r = 0.451, p = 0.0013), and (C) APRI
(r = 0.363, p = 0.0066).
740 Journal of Hepatology 20A total of 54 patients with NAFLD who underwent liver
biopsy and ARFI imaging with a Siemens Acuson System S2000
US system (Mochida Siemens Medical System, Tokyo, Japan)
were studied. ARFI imaging and the acquisition of the laboratory
data necessary for the determination of the APRI, the FIB4 score,
and NAFLD ﬁbrosis score were performed on the same day. Liver
biopsy showed that 44 (81.4%) patients had no or mild ﬁbrosis
(stage 0–2) and 10 (18.5%) had advanced ﬁbrosis (stage 3–4).
Shear wave speed was converted to shear stiffness, as previously
reported [2]. We investigated the correlation between the shear
stiffness and the APRI, FIB4 score, and NAFLD ﬁbrosis score
(Fig. 1). As expected, the shear wave stiffness was signiﬁcantly
correlated with the FIB4 score (R = 0.365, p = 0.0063) and NAFLD
ﬁbrosis score (R = 0.451, p = 0.0013). In our investigation, the
FIB4 score and NAFLD ﬁbrosis score were more signiﬁcantly cor-
related with the shear stiffness than the APRI (R = 0.363,
p = 0.0066).
Our results reconﬁrm the usefulness of ARFI shear stiffness for
predicting advanced ﬁbrosis in Japanese patients. ARFI can be
integrated into a conventional US system using conventional US
probes, and can therefore be estimated during standard US exam-
inations of the liver, which are routinely performed in patients
with chronic liver diseases. In conclusion, ARFI and shear stiffness
reconstruction is an excellent technology, because of its high sen-
sitivity, low additional cost, rapid, and lack of complications, and
it can be very easily accepted by the patients. It could be suitable
for evaluating the severity of hepatic ﬁbrosis in patients with
NAFLD in large cohort studies in the future, where it is difﬁcult
to perform liver biopsy.
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To the Editor:
Single nucleotide polymorphism (SNP) in the region of the inter-
leukin-28B (IL28B) gene has recently been associated with spon-
taneous and treatment-induced clearance of hepatitis C virus
infection [1–3]. The SNPs are located near the IL28B gene of chro-
mosome 19, implicating a role for its gene product, interferon-k3,
in the immune response to hepatitis C virus. The mechanisms by
which IL28B polymorphism effects the sensitivity to exogenous
peginterferon-a therapy is unclear at present.
We have read with interest the recent genome-wide associa-
tion study by Thompson et al. on peginterferon-a-induced cyto-
penia in chronic hepatitis C patients [4]. The authors state that
none of the IL28B polymorphisms known to be associated with
treatment induced viral clearance, correlated with the typical
peginterferon-a side effects thrombocytopenia and neutropenia
after 4 weeks of treatment. The authors suggest a possible liver
speciﬁcity of interferon-k by which the favorable IL28B polymor-
phism might result in increased viral clearance from the liver
with a reduced propensity for interferon-a-induced bone marrow
suppression.
We have three concerns regarding the study that might inﬂu-
ence interpretation of the observations made by the authors.
In the Individualized Dosing Efﬁcacy versus Flat Dosing to
Asses Optimal Pegylated Interferon Therapy (IDEAL) study,
3070 patients were treated, of whom 1654 completed the treat-
ment [5]. The patient group of the current GWAS study consisted
of 1284 out of 1604 patients who consented to genetic testing
and fulﬁlled the 80/80/80 adherence criteria. The majority of
patients studied in this analysis, therefore, probably derive from
the 1654 who completed treatment. Limiting the analysis to
adherent patients when studying dose-related side effects such
as peginterferon-induced cytopenia may appear justiﬁed at ﬁrst
glance. This approach, however, excludes the data from patients
who had dose reductions or were not able to complete treatment
for other peginterferon side effects, but who may have had con-
comitant peginterferon-induced cytopenias.
In the IDEAL study, patients were treated with either peginter-
feron-a-2b 1 lg/kg, 1.5 lg/kg or peginterferon-a-2a 180 lg/kg
weekly on a 1/1/1 randomized basis in combination with ribavi-
rin oral therapy [5]. The proportions of patients with neutropenia
who met the criterion for per protocol peginterferon-dose
reduction in this study were 12.5%, 19.4% and 21.1% of the
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patients treated with the low-dose peginterferon-a-2b (1 lg/kg)
versus the standard-dose peginterferon-a-2b (1.5 lg/kg) and
peginterferon-a-2a (180 lg/kg), respectively. The inclusion of
the low-dose peginterferon-a-2b arm in the current analy-
sis therefore obscures the severity of the observed cytopenias
in the two arms that were treated with the standard dose of
either peginterferon-a that is relevant for current clinical
practice.
In two recent publications by our group on peginterferon-
a-induced cytopenia, thrombocytopenia and neutropenia pro-
gressed to a nadir after 12 and 14 weeks of peginterferon-a
treatment, respectively [6,7]. The analysis performed by the
authors after only 4 weeks of treatment might therefore
underscore the severity of true peginterferon-a-induced cytope-
nia, obscuring a possible link with baseline IL28B polymorphism
as a marker of interferon sensitivity.
To rule out an inclusion bias, it is necessary to demonstrate
that the cytopenias observed in the reported 1284 patients do
not differ from those observed in the 1466 patients who did
not consent to genetic testing or in the 320 patients who did con-
sent but are not included in the analysis. We are also interested
to learn from the authors whether the absence of correlation with
IL28B polymorphism and peginterferon-induced cytopenia would
hold if the analysis were to be performed in both adherent and
non-adherent patients under treatment at week 12 and 18 from
the two standard peginterferon-a-2b 1.5 lg/kg and peginterfer-
on-a-2a 180 lg dosing groups, omitting the data from the low-
dose peginterferon-a-2b (1.0 lg/kg) group. An analysis of the
IL28B genotype distribution in the so-called ‘‘non-adherent’’ pop-
ulation that consented to genetic testing in comparison to the
reported ‘‘adherent’’ group would further help to clarify whether
a favorable IL28B polymorphism does in fact enhance viral
clearance without the occurrence of classical interferon-a side
effects.
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